Skip to main
SLNO

Soleno Therapeutics (SLNO) Stock Forecast & Price Target

Soleno Therapeutics (SLNO) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Soleno Therapeutics Inc.'s financial outlook appears strong, with a full-year 2026 revenue estimate rising to $462.3 million, reflecting robust sales performance. The company has achieved profitability and anticipates a cash position of approximately $500 million by the end of 2025, following an accelerated share repurchase program. Additionally, the early success of the VYKAT XR product, with expected sales between $189 million to $191 million since its launch, indicates a favorable trajectory, supported by significant market access and increasing prescriber engagement.

Bears say

The financial outlook for Soleno Therapeutics is negatively impacted by several fundamental issues, including potential market access and reimbursement challenges that could hinder the uptake of its product candidate, DCCR. Additionally, concerns regarding earlier-than-expected generic erosion of the DCCR franchise and the company's inability to optimize DCCR's value internationally contribute to a grim financial forecast. The combination of these factors has resulted in a significant 20% decline in the stock over the past month, reflecting investor apprehension regarding the company’s future performance.

Soleno Therapeutics (SLNO) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Soleno Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Soleno Therapeutics (SLNO) Forecast

Analysts have given Soleno Therapeutics (SLNO) a Buy based on their latest research and market trends.

According to 10 analysts, Soleno Therapeutics (SLNO) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $112.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $112.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Soleno Therapeutics (SLNO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.